



9-07-05

IFW

N 10/648,816

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	van Bruggen et al.	Examiner:	HOLLERAN, ANNE
Serial No.:	10/648,816	Group Art Unit:	1614
Filed:	August 26, 2003	Docket No.:	11669.0113USC1
Conf. No.:	5367	Customer No.:	23552
Title:	VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF		

CERTIFICATE UNDER 37 CFR 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on  
Sept 6, 2005.

By:

Name:

*Symunda Kraft*  
Symunda Kraft

REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Please revoke any existing Powers of Attorney, if any, and appoint the following  
attorneys and/or patent agents to prosecute this application and to transact all business in the U.S.

Patent and Trademark Office in connection therewith:

**23552**

PATENT TRADEMARK OFFICE

Please direct all correspondence in this application to Katherine M. Kowalchyk,  
P.O. Box 2903, Minneapolis, MN 55402-0903, telephone 612-371-5311.

Dated: August 25, 2005

By:

*Timothy R. Schwartz*  
Timothy R. Schwartz, Ph.D.  
Section Patent Counsel  
Authorized Corporate Signatory  
Genentech, Inc.

**CERTIFICATE UNDER 37 C.F.R. § 3.73(b)**


Genentech, Inc., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, CA 94080, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

- ☒ An assignment from the inventor(s), of the parent of the patent application identified above, a copy of which is attached hereto.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: August 25, 2005

By:   
Name: Timothy R. Schwartz, Ph.D.  
Title: Section Patent Counsel  
Genentech, Inc.  
Authorized Corporate Signatory